Latest epilepsy Stories

HOUSTON, June 11, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that it has entered into an exclusive technology license agreement with Imricor Medical Systems, Inc. to develop Magnetic Resonance Imaging ("MRI") compatible leads for use with the VNS Therapy® System (Vagus Nerve Stimulation). Imricor Medical Systems, based in Burnsville, Minnesota, is developing innovative MRI electrophysiology tools and has developed the world's only ablation catheter that is...

New research by scientists at the University of North Carolina School of Medicine may have pinpointed an underlying cause of the seizures that affect 90 percent of people with Angelman syndrome (AS), a neurodevelopmental disorder. Published online Thursday June 7, 2012 in the journal Neuron, researchers led by Benjamin D. Philpot, PhD, professor of cell and molecular physiology at UNC, describe how seizures in individuals with AS could be linked to an imbalance in the activity of specific...

LOUVAIN LA NEUVE, Belgium, June 7, 2012 /PRNewswire/ -- Treatment of Refractory Epilepsy by Vagus Nerve Stimulation to be available in Europe Neurotech s.a. (http://www.neurotech-int.eu), a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy. The surgically implanted ADNS-300 system delivers mild electrical pulses to the vagus...

Seizure severity and antiepileptic drug polytherapy among predictors of poor seizure outcomes A 25-year follow-up study reveals that 68% of patients with juvenile myoclonic epilepsy (JME) became seizure-free, with nearly 30% no longer needing antiepileptic drug (AED) treatment. Findings published today in Epilepsia, a journal of the International League Against Epilepsy (ILAE), report that the occurrence of generalized tonic-clonic seizures preceded by bilateral myoclonic seizures, and AED...

SCHAUMBURG, Ill., May 31, 2012 /PRNewswire/ -- Wellness Center USA, Inc. (OTCQB/OTCBB: WCUI), a Schaumburg IL based healthcare and nutraceutical company, today announced the signing of an agreement to acquire CNS Wellness, LLC (CNS), a Tampa, FL based cognitive neuroscience corporation specializing in the treatment of brain-based behavioral health disorders including developmental, emotional and stress-related problems. CNS's drug free and non-invasive methods provide...

LOS ANGELES, May 30, 2012 /PRNewswire/ -- Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS(TM)) on Post-Traumatic Stress Disorder...

HOUSTON, May 24, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the Jefferies 2012 Global Healthcare Conference on Thursday, June 7, 2012, in New York. Greg Browne, Senior Vice President and Chief Financial Officer, will speak at 10:00 AM Eastern Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the...

Researchers link seizure resistance to a protein that modifies cellular metabolism in the brain For decades, neurologists have known that a diet high in fat and extremely low in carbohydrates can reduce epileptic seizures that resist drug therapy. But how the diet worked, and why, was a mystery—so much so that in 2010, The New York Times Magazine called it "Epilepsy's Big, Fat Miracle." Now, researchers at Dana-Farber Cancer Institute and Harvard Medical School have proposed an...

A new study unravels a link between a protein that can modify cellular metabolism in the brain and seizure susceptibility. The research, published by Cell Press in the May 24th issue of the journal Neuron, may lead to the development of new treatments for epilepsy. Epilepsy is a disorder characterized by seizures, unpredictable and abnormal bursts of electrical activity in the brain. Some cases of epilepsy are resistant to traditional drug treatments but can be improved by a "ketogenic"...

HOUSTON, May 23, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that company co-founder, Reese S. Terry, Jr., is the recipient of the 2012 Professional Career Achievement Award from the Institute of Electrical and Electronic Engineers (IEEE) Engineering in Medicine & Biology Society. The award recognizes his significant contributions to therapeutic implantable devices and procedures for the treatment of epilepsy and drug-resistant chronic depression. Mr....